Phase
Condition
Atrial Flutter
Arrhythmia
Dysrhythmia
Treatment
N/AClinical Study ID
Ages 18-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- PVB in the long-term ECG recording (registration at least 18 hours): at least 500PVB/24 h or Supraventricular tachycardia (≥10 episodes/24h, outside sporting activity)or SVPB with vegetative symptoms (increased sweating, inner unrest, shaky hands, reddermographism) and no cardial pretreatment
Exclusion
Exclusion Criteria:
Left ventricular ejection fraction [EF] ≤ 40 %
Therapy with spironolactone > 50 mg/d
Therapy with torasemide > 20 mg/d
Supplementation or therapy with dietary supplements or drugs which contain vitaminsand minerals (above all potassium and magnesium)
Creatinine in the serum [i. S.]:≥ 1,4 mg/dl (men), ≥ 1,2 mg/dl (women)
Potassium i. S. ≤ 3,4 mmol/l and > 5,4 mmol/l
Magnesium i. S. ≤ 0,7 mmol/l and > 1,0 mmol/l
Acute and chronic diarrhea
Hyperthyroidism anamnestic or due to the current TSH (thyroid stimulatinghormone)-value
Pacemaker
Study Design
Connect with a study center
Elke Parsi assoc. Prof. MD
Berlin, 13053
GermanySite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.